Tasly Tianjin Biopharmaceutical Co., Ltd. clinical trials
Acquired by China Resources Pharmaceutical Group Limited, Mar 27, 2025 · source ↗
The registry lists 3 studies whose lead sponsor is Tasly Tianjin Biopharmaceutical Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 8, 2021.
Before and after it joined China Resources Pharmaceutical Group Limited
- First submitted before Tasly Tianjin Biopharmaceutical Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- 3
- First submitted after Tasly Tianjin Biopharmaceutical Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Tasly Tianjin Biopharmaceutical Co., Ltd.3 studies
Something wrong with this grouping? Tell us on the China Resources Pharmaceutical Group Limited page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All China Resources Pharmaceutical Group Limited studies →
- Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B PatientsStatus unknownNCT04189276Phase 2
Sponsor listed in the registry: Tasly Tianjin Biopharmaceutical Co., Ltd. · First submitted before Tasly Tianjin Biopharmaceutical Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid TumorsStatus unknownNCT04226066Phase 1/2
Sponsor listed in the registry: Tasly Tianjin Biopharmaceutical Co., Ltd. · First submitted before Tasly Tianjin Biopharmaceutical Co., Ltd. became part of China Resources Pharmaceutical Group Limited
- Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B PatientsCompletedNCT04168333Phase 1
Sponsor listed in the registry: Tasly Tianjin Biopharmaceutical Co., Ltd. · First submitted before Tasly Tianjin Biopharmaceutical Co., Ltd. became part of China Resources Pharmaceutical Group Limited